½ÃÀ庸°í¼­
»óǰÄÚµå
1589488

¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : À¯Çü, Á¦Ç°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Digital Diabetes Management Market by Type (Handheld Devices, Wearable Devices), Product (Apps, Devices), End-user - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 196 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 159¾ï ´Þ·¯·Î, 2024³â¿¡´Â 188¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 19.14%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 542¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

µðÁöÅÐ ´ç´¢º´ °ü¸®´Â ¸ð¹ÙÀÏ ¾Û, ¿þ¾î·¯ºí µð¹ÙÀ̽º, Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû µîÀÇ µðÁöÅÐ ±â¼úÀ» Ȱ¿ëÇÏ¿© ´ç´¢º´ ¸ð´ÏÅ͸µ, °ü¸®, Ä¡·á¸¦ ½Ç½ÃÇÕ´Ï´Ù. ÀÌ ºÐ¾ß´Â ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ È¿À²ÀûÀÎ °ü¸® Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ ´ç´¢º´ÀÇ ¼¼°è À¯º´·ü Áõ°¡·Î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½Ã°£ Æ÷µµ´ç ¸ð´ÏÅ͸µ, º¹¾à ¾Ë¸², °³ÀÎÈ­µÈ Ä¡·á °èȹ¿¡ ´ëÇÑ µ¥ÀÌÅÍ ºÐ¼® µî ´Ù¾çÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú Áøº¸, ½º¸¶Æ®Æù ¹× ÀÎÅÍ³Ý ¼­ºñ½º¿¡ ´ëÇÑ ¾×¼¼½º Áõ°¡, Á¤¹ÐÀÇ·á¿¡ ÁßÁ¡À» µÎ°í À̸¦ ÅëÇØ ¿¹Ãø ºÐ¼®À» °­È­Çϱâ À§ÇÑ ÀΰøÁö´ÉÀÇ ÅëÇÕ°ú Ç÷§Æû°£¿¡ µ¥ÀÌÅ͸¦ ¿øÈ°ÇÏ°Ô ±³È¯ÇÒ ¼ö ÀÖ´Â »óÈ£ ¿î¿ë °¡´ÉÇÑ ½Ã½ºÅÛ °³¹ß µîÀÌ ¼±È£µË´Ï´Ù. ÆÄÆ®³Ê½ÊÀº ä¿ëÀ» °¡¼ÓÈ­ÇÏ°í ½Å·Ú¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦»óÀÇ Àå¾Ö¹°, µðÁöÅÐ ÅøÀÇ »ç¿ë¿¡ °üÇÑ ±³À°À̳ª Æ®·¹ÀÌ´×ÀÇ º¸±ÞÀÇ Çʿ伺 µîÀÇ °úÁ¦µµ ³²¾Æ ÀÖ½À´Ï´Ù.¶Ç, Áö¿ª¿¡ ÀÇÇØ ÀÎÇÁ¶ó°¡ ´Ù¸£±â ¶§¹®¿¡ ±â¼ú¿¡ÀÇ ¾×¼¼½º°¡ Á¦ÇÑµÉ °¡´É¼ºµµ ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ¼º°ÝÀº ¿ªµ¿ÀûÀÌ¸ç ±Þ¼ÓÇÑ Çõ½Å°ú ÇÏÀÌÅ×Å© ¼±µµ ±â¾÷°ú ½ÅÈï ±â¾÷ ¸ðµÎÀÇ °æÀïÀ» Ư¡À¸·ÎÇÕ´Ï´Ù.Á¶»ç¿Í Çõ½ÅÀº »ç¿ëÀÚ Ä£È­ÀûÀÎ ÀÎÅÍÆäÀ̽º °­È­, µ¥ÀÌÅÍ º¸¾È ´ëÃ¥ °³¼±, ¼öÁý µ¥ÀÌÅͷκÎÅÍ ½Ç¿ëÀûÀÎ ÀλçÀÌÆ® È®´ë¿¡ ÁßÁ¡À» µÎ¾î¾ß ÇÕ´Ï´Ù. ¶ÇÇÑ, ÃæºÐÇÑ ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÑ ½ÃÀåÀ¸·Î È®ÀåÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼Ç °³¹ßµµ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ ÀÌ¿ëÇϱâ À§ÇØ ÀÌÇØ°ü°èÀÚ´Â º¸´Ù ¸íÈ®ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©À» Á¦Ã¢Çϰí À¯È¿¼º°ú È®À强À» ½ÇÁõÇϱâ À§ÇÑ ÆÄÀÏ·µ ÇÁ·Î±×·¥¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. Áö¿ª °Ç°­ °ü¸® »ýŰ踦 ÀÌÇØÇÏ´Â °ÍÀº Áö¿ª ¿ä±¸¿¡ ¸Â°Ô ¼Ö·ç¼ÇÀ» Á¶Á¤ÇÏ°íº¸´Ù ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» º¸ÀåÇÏ´Â µ¥ ÇÙ½ÉÀÔ´Ï´Ù. ¾÷°è °ü°èÀÚ¿Í ±ÔÁ¦ ´ç±¹ÀÌ Çù·ÂÇÔÀ¸·Î½á Àü°³°¡ ´õ¿í ÇÕ¸®È­µÇ°í Áö¼ÓÀûÀÎ Çõ½ÅÀ» Á¶ÀåÇϴ ȯ°æÀÌ Á¶¼ºµË´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 159¾ï ´Þ·¯
¿¹Ãø³â(2024) 188¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 542¾ï ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 19.14%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°èÀÇ ´ç´¢º´ ȯÀÚ Áõ°¡
    • Áúº´ °ü¸®¸¦ À§ÇÑ ½º¸¶Æ®Æù ¾Û º¸±Þ¼ö Áõ°¡
    • µðÁöÅÐ ´ç´¢º´ °ü¸®¿¡ À־ÀÇ Çõ½Å°ú ½ÅÁ¦Ç° °³¹ß
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±â¼úÀûÀÎ ¹®Á¦·Î ¼¿ÇÁ ÄÉ¾î ¾ÛÀ» ÀÌ¿ëÇÒ ¼ö ¾ø´Â ȯÀÚ
    • µð¹ÙÀ̽ºÀÇ °íºñ¿ë
  • ½ÃÀå ±âȸ
    • ¾ðÁ¦ ¾îµð¼­³ª °Ç°­ ¹®Á¦¸¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â µðÁöÅÐ ±â¼ú ¼ö¿ä
    • È¿¼Ò Æ÷µµ´ç ¹ÙÀÌ¿À ¼¾¼­ÀÇ ÃâÇö
  • ½ÃÀåÀÇ °úÁ¦
    • ȯÀÚÀÇ ³·Àº ÀÎÁöµµ

Porter's Five Forces : µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ °¡´ÉÇÕ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Àü ¼¼°è¿¡¼­ ´ç´¢º´ ȯÀÚ Áõ°¡
      • Áúº´ °ü¸®¸¦ À§ÇÑ ½º¸¶Æ®Æù ¾ÛÀÇ º¸±ÞÀÌ Áõ°¡
      • µðÁöÅÐ ´ç´¢º´ °ü¸®¿¡ À־ÀÇ Çõ½Å°ú ½ÅÁ¦Ç° °³¹ß
    • ¾ïÁ¦¿äÀÎ
      • ±â¼úÀûÀÎ ¹®Á¦·Î ȯÀÚ°¡ ¼¿ÇÁ ÄÉ¾î ¾ÛÀ» »ç¿ëÇÒ ¼ö ¾ø½À´Ï´Ù
      • µð¹ÙÀ̽ºÀÇ °íºñ¿ë
    • ±âȸ
      • ¾ðÁ¦ ¾îµð¼­³ª °Ç°­ ¹®Á¦¸¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â µðÁöÅÐ ±â¼ú ¼ö¿ä
      • È¿¼Ò Æ÷µµ´ç ¹ÙÀÌ¿À¼¾¼­ÀÇ ÃâÇö
    • °úÁ¦
      • ȯÀÚ »çÀÌÀÇ ÀνÄÀÇ ÇѰè
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : À¯Çüº°

  • ÇÚµåÇïµå µð¹ÙÀ̽º
  • ¿þ¾î·¯ºí µð¹ÙÀ̽º

Á¦7Àå µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : Á¦Ç°º°

  • ¾Û
    • µðÁöÅÐ ´ç´¢º´ °ü¸® ¾Û
    • üÁß°ú ´ÙÀÌ¾îÆ® °ü¸® ¾Û
  • µð¹ÙÀ̽º
    • Áö¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛ
    • ½º¸¶Æ® Ç÷´çÄ¡ ÃøÁ¤±â
    • ½º¸¶Æ® Àν¶¸° Ææ
    • ½º¸¶Æ® Àν¶¸° ÆßÇÁ/Æó¼â ·çÇÁ ÆßÇÁ¿Í ½º¸¶Æ® Àν¶¸° ÆÐÄ¡

Á¦8Àå µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø°ú ´ç´¢º´ Àü¹® Ŭ¸®´Ð
  • ¼¿ÇÁ/ÀçÅà ÇコÄɾî

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Agamatrix, Inc.
  • Ascensia Diabetes Care Holdings AG
  • Azumio Inc.
  • B. Braun SE
  • BeatO by Health Arx Technologies Pvt. Ltd.
  • Becton, Dickinson and Company
  • DarioHealth Corp.
  • Dassault Systemes SE
  • Dexcom, Inc.
  • F. Hoffmann-La Roche AG
  • Glooko, Inc.
  • GlucoMe
  • GlucoTab by decide Clinical Software GmbH
  • Health2Sync by H2, Inc.
  • Insulet Corporation
  • Lark Technologies, Inc.
  • LifeScan IP Holdings, LLC
  • Medtronic PLC
  • Novo Nordisk A/S
  • Omada Health Inc.
  • One Drop by Informed Data Systems Inc.
  • Orpyx Medical Technologies Inc.
  • Pendiq GmbH
  • Sharecare, Inc.
  • SocialDiabetes SL
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • Ypsomed AG
BJH 24.11.21

The Digital Diabetes Management Market was valued at USD 15.90 billion in 2023, expected to reach USD 18.85 billion in 2024, and is projected to grow at a CAGR of 19.14%, to USD 54.20 billion by 2030.

Digital Diabetes Management involves utilizing digital technologies such as mobile apps, wearable devices, and cloud-based platforms to monitor, manage, and treat diabetes. This sector is crucial due to the rising global prevalence of diabetes, which necessitates efficient management and continuous monitoring to prevent complications. Applications span real-time glucose monitoring, medication reminders, and data analytics for personalized treatment plans. End-users primarily include individuals with diabetes, healthcare providers, and researchers focusing on chronic disease management. Growth in this market is driven by technological advancements, increased accessibility to smartphones and internet services, and a growing emphasis on precision medicine. Opportunities include the integration of artificial intelligence to enhance predictive analytics and the development of interoperable systems that can seamlessly exchange data across platforms. Partnerships between technology companies and healthcare providers can also accelerate adoption and enhance trust. However, challenges persist, such as data privacy concerns, regulatory hurdles, and the need for widespread education and training in the use of digital tools. Infrastructure variances in different regions may also limit technology access. The market's nature is dynamic, characterized by rapid innovation and competition from both tech giants and startups. Research and innovation should focus on enhancing user-friendly interfaces, improving data security measures, and expanding actionable insights from collected data. Developing cost-effective solutions that can be scaled to underserved markets is also essential. To capitalize on these opportunities, stakeholders should advocate for clearer regulatory frameworks and invest in pilot programs to demonstrate efficacy and scalability. Understanding regional healthcare ecosystems will be key in tailoring solutions to local needs, thus ensuring broader adoption. Collaborative efforts between industry players and regulatory bodies can further streamline deployment and foster an environment conducive to continuous innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 15.90 billion
Estimated Year [2024] USD 18.85 billion
Forecast Year [2030] USD 54.20 billion
CAGR (%) 19.14%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Digital Diabetes Management Market

The Digital Diabetes Management Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Prevalence of Diabetic Patients Worldwide
    • Increasing Number of Smartphone Apps Penetration for Disease Management
    • Innovation and New Product Development in Digital Diabetes Management
  • Market Restraints
    • Patients' Inability to use Self-Care Apps due to Technical Issues
    • High Cost of Devices
  • Market Opportunities
    • Demand for Anytime-Anywhere Digital Technology for Monitoring Health Issues
    • Emergence of Enzyme Glucose Biosensors
  • Market Challenges
    • Limited Awareness among the Patient

Porter's Five Forces: A Strategic Tool for Navigating the Digital Diabetes Management Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Digital Diabetes Management Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Digital Diabetes Management Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Digital Diabetes Management Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Digital Diabetes Management Market

A detailed market share analysis in the Digital Diabetes Management Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Digital Diabetes Management Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Digital Diabetes Management Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Digital Diabetes Management Market

A strategic analysis of the Digital Diabetes Management Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Digital Diabetes Management Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories, Inc., Agamatrix, Inc., Ascensia Diabetes Care Holdings AG, Azumio Inc., B. Braun SE, BeatO by Health Arx Technologies Pvt. Ltd., Becton, Dickinson and Company, DarioHealth Corp., Dassault Systemes SE, Dexcom, Inc., F. Hoffmann-La Roche AG, Glooko, Inc., GlucoMe, GlucoTab by decide Clinical Software GmbH, Health2Sync by H2, Inc., Insulet Corporation, Lark Technologies, Inc., LifeScan IP Holdings, LLC, Medtronic PLC, Novo Nordisk A/S, Omada Health Inc., One Drop by Informed Data Systems Inc., Orpyx Medical Technologies Inc., Pendiq GmbH, Sharecare, Inc., SocialDiabetes S.L., Tandem Diabetes Care, Inc., Terumo Corporation, and Ypsomed AG.

Market Segmentation & Coverage

This research report categorizes the Digital Diabetes Management Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Handheld Devices and Wearable Devices.
  • Based on Product, market is studied across Apps and Devices. The Apps is further studied across Digital Diabetes Management Apps and Weight & Diet Management Apps. The Devices is further studied across Continuous Glucose Monitoring (CGM) Systems, Smart Glucose Meters, Smart Insulin Pens, and Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches.
  • Based on End-user, market is studied across Hospitals & Specialty Diabetes Clinics and Self/Home Healthcare.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Diabetic Patients Worldwide
      • 5.1.1.2. Increasing Number of Smartphone Apps Penetration for Disease Management
      • 5.1.1.3. Innovation and New Product Development in Digital Diabetes Management
    • 5.1.2. Restraints
      • 5.1.2.1. Patients' Inability to use Self-Care Apps due to Technical Issues
      • 5.1.2.2. High Cost of Devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Demand for Anytime-Anywhere Digital Technology for Monitoring Health Issues
      • 5.1.3.2. Emergence of Enzyme Glucose Biosensors
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Awareness among the Patient
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Digital Diabetes Management Market, by Type

  • 6.1. Introduction
  • 6.2. Handheld Devices
  • 6.3. Wearable Devices

7. Digital Diabetes Management Market, by Product

  • 7.1. Introduction
  • 7.2. Apps
    • 7.2.1. Digital Diabetes Management Apps
    • 7.2.2. Weight & Diet Management Apps
  • 7.3. Devices
    • 7.3.1. Continuous Glucose Monitoring (CGM) Systems
    • 7.3.2. Smart Glucose Meters
    • 7.3.3. Smart Insulin Pens
    • 7.3.4. Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches

8. Digital Diabetes Management Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals & Specialty Diabetes Clinics
  • 8.3. Self/Home Healthcare

9. Americas Digital Diabetes Management Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Digital Diabetes Management Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Digital Diabetes Management Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ACON Laboratories, Inc.
  • 3. Agamatrix, Inc.
  • 4. Ascensia Diabetes Care Holdings AG
  • 5. Azumio Inc.
  • 6. B. Braun SE
  • 7. BeatO by Health Arx Technologies Pvt. Ltd.
  • 8. Becton, Dickinson and Company
  • 9. DarioHealth Corp.
  • 10. Dassault Systemes SE
  • 11. Dexcom, Inc.
  • 12. F. Hoffmann-La Roche AG
  • 13. Glooko, Inc.
  • 14. GlucoMe
  • 15. GlucoTab by decide Clinical Software GmbH
  • 16. Health2Sync by H2, Inc.
  • 17. Insulet Corporation
  • 18. Lark Technologies, Inc.
  • 19. LifeScan IP Holdings, LLC
  • 20. Medtronic PLC
  • 21. Novo Nordisk A/S
  • 22. Omada Health Inc.
  • 23. One Drop by Informed Data Systems Inc.
  • 24. Orpyx Medical Technologies Inc.
  • 25. Pendiq GmbH
  • 26. Sharecare, Inc.
  • 27. SocialDiabetes S.L.
  • 28. Tandem Diabetes Care, Inc.
  • 29. Terumo Corporation
  • 30. Ypsomed AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦